Trial Profile
A Single-centre, retrospective study to evaluate lymphopenia and its association with objective response to PD-1 inhibitor therapy (nivolumab or pembrolizumab) in patients with solid tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 06 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology